Arrayit Corporation (ARYC)

[StockDetective]

My Arrayit Corp (ARYC) visit:

I spoke with Rene & Mark Schena face-to-face and also went hands on with their technology like many others have taken the time to do. I highly recommend it to anyone who has not done so already. I was impressed and this really boosted my confidence as a shareholder.

During the tour I was given the option for a free food intolerance test or an allergy test. I went with the allergy test. As I added my four drops of blood on the blood card, I observed hundreds of Pinnertests on the lab table waiting to be processed. If I had to guess, I would say roughly between 200-300 tests. I was told it was one days shipment... Now that’s Pinnertest alone and before all the big endorsements even came about.

Time to suit up, enter the clean room, & go hands on in the testing process...

Most of the equipment being used to process these test is reusable. Mass production would not be a problem for this company as robust machinery do most of the work.

I also asked about the OvaDx product and was advised that the details of the test were confidential at the time. As I pressed the issue a bit further was told that there was going to be a press release in the future regarding the matter. The subject was then changed as the good doctor advised me that he had said too much already.

When I finally viewed my allergy test report the name Dr Julie A. Taguchi showed up as the lab director of Arrayit. The report also comes with Arrayit’s CLIA laboratory number.

https://investorshub.advfn.com/uimage/uploads/2019/6/7/hyias84AA70FE-19A8-4E39-8F73-6FF2DB6E26D1.jpeg

https://www.cms.gov/apps/clia/clia_start.asp?CLIANum=05D2147467&LabName=&GeoCity=&state=AK&GeoZip=&appType=%25&isSubmitted=clia2

Dr Julie A. Taguchi is also described on the OvaDx product details down below...

Dr Julie A. Taguchi at Arrayit Corp announcing a sweet discovery?

https://www.instagram.com/p/BgMsxken3yb/

From the website:

Can ovarian cancer be cured by early stage detection and treatment?

Yes. According to Dr. Julie A. Taguchi, MD, of the Sansum Medical Clinic in Santa Barbara, CA, surgical removal of stage IA ovarian tumors effectively cures ovarian cancer in a large percentage of patients without the requirement for chemotherapy. According to the medical literature, the 20-year survival rate for stage IA patients is very good.

http://www.arrayit.com/Microarray_Diagnostics/Ovarian_Cancer_Forum/ovarian_cancer_forum.html

Doctors and nurses currently use 15 million CA-125 tests per year to monitor ovarian cancer, generating approximately $2 billion in worldwide revenue. Capturing 1% of the ovarian cancer monitoring market would generate $97.5 million in annual revenues for Arrayit through the manufacture and sale of 150,000 OvaDx® tests at $650 per test. Our Sunnyvale laboratories have more than adequate capacity to process 150,000 OvaDx® tests per year upon FDA approval.

This website was updated last year.

In Development

Arrayit Corporation and Avant Diagnostics, Inc. provide the market’s first large panel biomarker monitoring test for ovarian cancer (OVC). OvaDx® is advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.

http://arrayit.com/Microarray_Diagnostics/OvaDx_Ovarian_Cancer_Test/ovadx_ovarian_cancer_test.html


More catalysts under way with Parkinson’s Disease PDx™ test:

The Parkinson’s Institute video link:

Arrayit has leveraged the company’s patented and proprietary microarray discovery platform to decipher the molecular basis of Parkinson’s Disease (PD). This important research project offers exciting promise for the pre-symptomatic and post-symptomatic diagnosis and treatment of this serious neurodegenerative condition. Arrayit is currently seeking a strategic partner to accelerate FDA approval of the Arrayit PDx™ Parkinson’s Diagnostic Test, speed the benchmarking of PDx™ as a companion diagnostic, and determine and enhance the efficacy of pipeline therapeutic proteins and small molecules.

Arrayit PDx™ Pre-Symptomatic Test for Parkinson’s Disease will be submitted to the United Sates Food and Drug Administration (FDA) as a 510(k) submission in the near future.

http://www.arrayit.com/Microarray_Diagnostics/Parkinsons_Disease/parkinsons_disease.html

Arrayit Corporation and The Parkinson's Institute Research Collaboration

“This collaboration provides an important first step towards unraveling the mysteries of Parkinson's disease," stated Dr. Mark Schena, Ph.D., Arrayit President. "We look forward to working with The Parkinson's Institute to decipher the molecular basis of the disease," he continued. The Parkinson's Institute Assistant Professor Dr. Birgitt Schuele, M.D. added, "Parkinson's disease represents a serious and challenging medical condition. We are pleased to be deploying Arrayit technology to combat this illness.”

About The Institute

WHO WE ARE
The mission of The Parkinson’s Institute (The PI) is to provide comprehensive patient care, while discovering new treatment options to improve the quality of life for all Parkinson’s disease (PD) patients. As America’s only independent non-profit organization combining research and patient care for PD under one roof, we are committed to changing the landscape of movement disorder treatment and research. Since its founding, The PI has helped thousands of PD patients better manage their disease, developed new treatments for PD, and published groundbreaking research aimed to close the gap between science and practical care. By focusing on all three avenues of PD - cause, care and cure - The PI is a powerful force in PD research.

http://www.thepi.org/about-the-institute/

Arrayit Scientific Solutions Inc...Marketing a test for Parkinson’s Disease.

https://www.nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=dsbOEiMfG9LB4qKRsPW%252bzw%253d%253d&nt7=0


http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Selected_b/arrayit_corporation_selected_by_silicom_ventures_to_present_at_t.html

https://mobile.twitter.com/PrecisionMedUS

The latest The Precision Medicine Daily! (link: https://paper.li/PrecisionMedUS/1462454124?edition_id=78b41830-8948-11e9-8c4e-0cc47a0d164b) paper.li/PrecisionMedUS… Thanks to
@harvard_data

@arrayit

@letswinpc
#precisionmedicine #cancer